Treatment indications HepaGam B™ Hepatitis B Immune Globulin
Intravenous (Human) is indicated for the prevention of
hepatitis B recurrence following liver transplant in HBsAg positive liver transplant patients.
HepaGam B™ is also indicated in the event of:
Acute exposure to blood containing HBsAg
Perinatal exposure of infants born to HBsAg-positive
mothers
Sexual exposure to HBsAg-positive people
Household exposure to people with acute HBV infection
Household exposure of infants less than 12
months old whose mother or primary care giver is
positive for HBsAg
For more information on HepaGam B™,
please contact Apotex at
877-HepaGamB (437-2426).
HepaGam B™ (Hepatitis B Immune Globulin Intravenous (Human)), is a purified gamma globulin (IgG) fraction of human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Individuals known to have severe, potentially life-threatening reactions to human globulin should not receive HepaGam B™ or any other immune globulin (Human). Individuals who are deficient in IgA may have the potential for developing IgA antibodies and have severe, potentially life-threatening allergic reactions. The maltose contained in HepaGam B™ can interfere with some types of blood glucose monitoring systems. Only testing Systems that are glucose-specific should be used in patients receiving HepaGam B™. This interference can result in Falsely elevated glucose readings that can lead to untreated hypoglycemia or to inappropriate insulin administration, resulting In life-threatening hypoglycemia. The most common expected adverse drug reactions for immune globulins like HepaGam B™ are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.